^
    13h
    Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative (clinicaltrials.gov)
    P1/2, N=108, Completed, Sunshine Lake Pharma Co., Ltd. | Active, not recruiting --> Completed | N=158 --> 108
    Trial completion • Enrollment change
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation
    |
    gefitinib • ningetinib (CT053PTSA)
    21h
    OptiTROP-Lung01: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=110, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
    |
    cisplatin • carboplatin • Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    22h
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    23h
    IMP3-saRNA Vaccine in Advanced NSCLC (clinicaltrials.gov)
    P1, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • ALK positive • EGFR wild-type • ROS1 positive
    1d
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Trial completion date: Dec 2029 --> Dec 2028 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Zegfrovy (sunvozertinib)
    1d
    Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC. (PubMed, Front Mol Biosci)
    Specifically, the mean OS was longer for patients with higher VAF in both the overall cohort and in subgroups with EGFR exon 19 deletions and exon 21 L858R mutations. These findings suggest that VAF could serve as a valuable predictive biomarker for treatment outcomes in EGFR-mutated NSCLC patients, highlighting its potential role in personalizing treatment strategies.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    2d
    Impact of EGFR Mutations on Survival and Clinical Response in Non-Small Cell Lung Cancer in a Tertiary Care Hospital. (PubMed, Clin Transl Sci)
    EGFR mutation status, brain metastases, and clinical response are key predictors of survival in NSCLC patients. Integrating genetic screening, timely management of brain metastases, and early assessment may enhance personalized treatment and improve prognosis.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive • EGFR negative
    3d
    TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy. (PubMed, Respir Res)
    Our study revealed that TGM2 is a potential therapeutic target or biomarker for predicting acquired EGFR-TKI resistance in EGFR-mutated NSCLC.
    Preclinical • Journal
    |
    SQSTM1 (Sequestosome 1) • TGM2 (Transglutaminase 2) • PLIN2 (Perilipin) • GLS2 (Glutaminase 2)
    |
    EGFR mutation • EGFR expression
    |
    chloroquine phosphate • etomoxir (MIQ-001)
    3d
    Osimertinib-induced interstitial lung disease insights from faers signal detection and network toxicology analysis. (PubMed, BMC Cancer)
    1 Article types. Original Research.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    4d
    Primary Gliosarcoma With Mesenchymal Differentiation Resembling Follicular Dendritic Cell Sarcoma. (PubMed, Neuropathology)
    This case represents the first documented instance of primary gliosarcoma with FDCS differentiation, thereby expanding its known differentiation spectrum. Furthermore, it demonstrates the necessity of separately analyzing each histological component in the diagnosis of challenging cases.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • KDR (Kinase insert domain receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CR1 (Complement C3b/C4b Receptor 1) • FCER2 (Fc Fragment Of IgE Receptor II) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    EGFR mutation • EGFR amplification • PTEN mutation • KIT mutation • MGMT promoter methylation • PDGFRA mutation
    5d
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)